Abstract 164P
Background
Immune checkpoint inhibitors (ICI) were demonstrated to extend survival in patients with metastatic esophageal squamous cell carcinoma (ESCC). However, the role of ICI in locally advanced ESCC is not yet established. Herein, we conducted a retrospective study to evaluate the efficacy and safety of ICI plus neoadjuvant concurrent chemoradiotherapy (CCRT) for patients with locally advanced ESCC.
Methods
ESCC patients treated with neoadjuvant CCRT were retrospectively recruited into our study. Patients were classified into ICI-CCRT and CCRT according to regimens during CCRT. ICI-CCRT referred to ICI plus chemoradiotherapy while CCRT referred to chemoradiotherapy alone. Kaplan-Meier curves were estimated for recurrent-free survival (RFS) and overall survival (OS).
Results
A total of 150 patients were enrolled into our study, with 43 patients in ICI-CCRT and 107 patients in CCRT group. The median age was 58.5 years old of our patients and median follow-up period were 22 months. As for patients in ICI-CCRT, 33 patients received nivolumab plus CCRT and 10 patients received pembrolizumab plus CCRT. The median RFS was not reach (NR) versus 16.2 months in ICI-CCRT and CCRT group, respectively (p= 0.016). The median OS was not reach (NR) versus 20.0 months in ICI-CCRT and CCRT group, respectively (p= 0.002). The response rates were significantly higher in IC-CCRT, accounting for 74 % versus 65 % in ICI-CCRT arm and CCRT arm, respectively. Multivariate analysis showed ICI-CCRT was an independent predictor associated with survival. Grade 3/4 adverse events were comparable between each group.
Conclusions
Neoadjuvant ICI-CCRT is superior to CCRT for locally advanced ESCC patients with similar toxicity profiles. Further prospective studies are warranted to validate our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract